Mack, Heather G. http://orcid.org/0000-0001-9756-1098
Britten-Jones, Alexis Ceecee http://orcid.org/0000-0002-1101-2870
McGuinness, Myra B. http://orcid.org/0000-0002-5422-040X
Chen, Fred K. http://orcid.org/0000-0003-2809-9930
Grigg, John R. http://orcid.org/0000-0002-6763-8119
Jamieson, Robyn V.
Edwards, Thomas L.
De Roach, John http://orcid.org/0000-0002-2682-5380
O’Hare, Fleur http://orcid.org/0000-0002-0022-0527
Martin, Keith R.
Ayton, Lauren N. http://orcid.org/0000-0001-9907-084X
Funding for this research was provided by:
Retina Australia, grant not numbered
Department of Health | National Health and Medical Research Council (GNT1116360, MRF1142962, GNT1188694, GNT1116360, GNT1116360, GNTMRF1151055, GNT1195713)
Victorian State Government Operational Infrastructure Support Program. Grant not numbered.
Retina Australia, grant not numbered.
Article History
Received: 9 April 2022
Revised: 16 August 2022
Accepted: 26 August 2022
First Online: 2 October 2022
Competing interests
: The authors declare the following relationships: HGM: Novartis (C); ACB-J: none; MBMcG: none; FKC: Novartis (C), PYC Therapeutics (C), ProQR Therapeutics (C), Editas Medicine (C); JRG: Novartis (C); RVJ: Novartis (C); TLE: Novartis (C); JDR: none; FO’H: none; KRM: Allergan (C,R), Santen (C,R), Novartis (C,R), Roche (C), Quethera (C,O), Ikarovec (O), Astellas (C); LNA: none.
: Ethics approval was obtained from the University of Melbourne Human Research Ethics Committee (#2057534). This study was undertaken in accordance with the Declaration of Helsinki and with Australian National Statement on Ethical Conduct in Human Research.
: All participants consented to participating in the study prior to undertaking the survey, after explanation of the nature and possible consequences of the survey, using online consent, verbal consent, or by signing the paper consent form [CitationRef removed].